August 4, 2022

Isofol held a presentation
in conjunction with the press release
of the top-line results in the AGENT study

Listen to the audiocast if you are an investor, analyst or work with media >>

Startpage 3

This website is intended for use by residents of Sweden only

About Isofol

Isofol Medical AB (publ) is a biotech company that was founded in 2008 and is developing a new drug candidate for the treatment of advanced colorectal cancer. Colorectal cancer (CRC) is the third most common form of cancer worldwide and the need for more effective drugs to treat this disease is very high.


Upcoming Events

  • August 23, 2022 - August 23, 2022
    Interim Report Q2 2022
  • August 31, 2022 - August 31, 2022
    Redeye Late Stage Life Science conference 2022
  • September 07, 2022 - September 08, 2022
    Pareto Securities' 13th annual Healthcare Conference 2022, Stockholm
    Isofol will attend the conference and CEO, Ulf Jungnelius, will give a presentation on September 7 at 14:30 CEST.